163 Hits
163 Hits
222 Hits
222 Hits
1079 Hits
1079 Hits
815 Hits
815 Hits
1056 Hits
1056 Hits
1588 Hits
1588 Hits
1652 Hits
1652 Hits
1497 Hits
1497 Hits
1214 Hits
1214 Hits
1835 Hits
1835 Hits
2238 Hits
2238 Hits
1925 Hits
1925 Hits
As of January 2021, parties will no longer have free choice on whether a hearing (oral proceedings) during examination or opposition is in person or via video conferencing before the European Patent Office (EPO). Video conferences will be the default. 12 months ago, we would have had to fight for a hearing (oral proceedings) to be held with t...
1979 Hits
1979 Hits
A Supplementary Protection Certificate (SPC) can provide up to five years additional protection for a patented active ingredient of a pharmaceutical product that has received a marketing authorisation. The objective is to compensate a patent holder for the delay in being able to use the patent by the need to obtain the marketing authorisation. An S...
1271 Hits
1271 Hits
We have previously written about our involvement in filing and prosecuting patent applications for two inventions created by the AI inventor DABUS, and naming DABUS (the true deviser of the inventions) as the inventor.The UK IPO found the inventions to be both novel and inventive, and therefore, in principle, protectable by patent. ...
1423 Hits
1423 Hits
Ever since the Decision issued back in 1997 in the case of Biogen v Medeva the concept of insufficiency has been extended, particularly in the chemical and biotech fields, to include claims that have "excessive breadth" (so-called "Biogen insufficiency"). The Courts in the UK have applied this frequently to revoke patents that they decide clai...
1957 Hits
1957 Hits
Regeneron Pharmaceuticals' European patent EP 1360287 and its divisional EP 2264163 relate to methods of producing transgenic mice able to produce antibodies having human sequences, and the mice produced thereby. These patents covered the idea of producing mice having mixed human-murine gene sequences that could be subsequently modified t...
2044 Hits
2044 Hits
2296 Hits
2296 Hits
©
2007 - 2022
Williams Powell
All rights reserved.
Williams Powell are regulated by IPREG whose code of conduct can be found here.These pages aim to provide a source of information for both non-professional enquirers e.g. inventors and their companies in the U.K. and professional consultants and advisers throughout the rest of the world. The pages are not intended to provide legal advice, which will only be provided on direct application to us in the formal context of a client/attorney relationship.
The information provided is correct to the best of our knowledge and belief, but is provided without obligation or guarantee. It will be updated from time to time as needed.